Pacific Biosciences of California, Inc. PACB

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

• GlobeNewswire Inc. 5 oct

  Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR

  The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.

  

• Zacks Investment Research 2 oct

  Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts

  Pacific Biosciences of California (PACB) stock rose 1.2% to $2.54, outperforming the S&P 500's 0.73% gain. Despite a 93.08% monthly surge, the company faces headwinds with projected EPS of -$0.13 (down 8.33% YoY) and revenue of $37.86 million (down 1.51% YoY). PACB holds a Zacks Rank of #4 (Sell) with unchanged consensus estimates over the past 30 days.

  

• Zacks Investment Research 17 sept

  Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today

  Pacific Biosciences of California (PACB) gained 2.99% on September 17, 2026, outperforming the S&P 500's 1.14% gain. The stock has climbed 5.51% over the past month. However, the company faces headwinds with projected earnings decline of 8.33% year-over-year and a Zacks Rank of #4 (Sell), indicating negative analyst sentiment despite recent price momentum.

  

• GlobeNewswire Inc. 6 ago

  AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision Medicine

  Artificial intelligence is fundamentally restructuring bioinformatics, compressing drug discovery timelines and attracting billions in venture capital. AI tools like AlphaFold and generative biology platforms are delivering measurable ROI, with companies achieving 99% cost reductions in drug discovery. North America leads adoption, supported by federal programs and substantial R&D investments from established life sciences players.